Drug
Cilofexor clinical trials
Also written GS-9674.
- studies test it
- 12
- open now
- 0
- in phase 3
- 1
- first study started
- 2013
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2016 (6)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 6 |
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Gilead Sciences (11) · Phenex Pharmaceuticals AG (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses cilofexor is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Gilead SciencesNCT04971785Written as Cilofexor (CILO)/Firsocostat (FIR)
- Study of Cilofexor in Adults With Primary Sclerosing CholangitisTerminatedPhase 3Gilead SciencesNCT03890120Written as Cilofexor
- Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisTerminatedPhase 1Gilead SciencesNCT04060147Written as Cilofexor
- Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Gilead SciencesNCT02781584Written as CILO
- Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Gilead SciencesNCT03987074Written as Cilofexor
- Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without CirrhosisCompletedPhase 2Gilead SciencesNCT02943460Written as Cilofexor
- Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic FunctionCompletedPhase 1Gilead SciencesNCT02808312Written as Cilofexor
- Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Gilead SciencesNCT03449446Written as CILO
- Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and PharmacodynamicsCompletedPhase 1Gilead SciencesNCT02654002Written as Cilofexor
- Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without CirrhosisTerminatedPhase 2Gilead SciencesNCT02943447Written as Cilofexor
- Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Gilead SciencesNCT02854605Written as GS-9674
- Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) PatientsCompletedPhase 2Phenex Pharmaceuticals AGNCT01999101Written as Px-104
Codes
What other systems call cilofexor · ClinicalTrials.gg INT001622
- MeSH (NLM) C000717094cilofexorOne source NLM
- UNII (FDA) YUN2306954CILOFEXORConfirmed FDA, NLM, Wikidata
- Wikidata Q105334909cilofexorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169848CilofexorOne source FDA
- DrugBank DB15168One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000717094 | cilofexor | One source NLM |
| UNII (FDA) | YUN2306954 | CILOFEXOR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105334909 | cilofexor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169848 | Cilofexor | One source FDA |
| DrugBank | DB15168 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.